Ekso Bionics - EKSO Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EKSO shares.
View EKSO analyst ratings or view top-rated stocks.

1 brokerages have issued 1-year price objectives for Ekso Bionics' shares. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 484.4% from the stock's current price.
View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts.

Ekso Bionics' stock was trading at $1.19 at the beginning of the year. Since then, EKSO stock has increased by 29.4% and is now trading at $1.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our EKSO earnings forecast.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings data on Monday, November, 1st. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10. The business earned $3.05 million during the quarter, compared to the consensus estimate of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same period in the previous year, the business posted ($0.52) earnings per share.

Ekso Bionics shares reverse split on the morning of Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA).

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (3.38%), Legato Capital Management LLC (0.29%), Strategic Wealth Investment Group LLC (0.22%), Simplex Trading LLC (0.00%), Susquehanna International Group LLP (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman.
View institutional ownership trends.

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EKSO stock can currently be purchased for approximately $1.54.

Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $20.24 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647.